A Fifty-Two-Week, Multicenter, Open-Label Study Evaluating the Long-Term Safety and Tolerability of Saredutant in Adult and Elderly Patients With Major Depressive Disorder.
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2012
At a glance
- Drugs Saredutant (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Sponsors Sanofi
- 16 Feb 2012 Actual end date (Apr 2007) added as reported by ClinicalTrials.gov.
- 16 Feb 2012 Actual patient number (365) added as reported by ClinicalTrials.gov.
- 12 Jun 2007 Status change from in progress to completed.